Philadelphia chromosome-positive acute lymphoblastic leukemia

Cancer

Volumn 117, Issue 8, 2011, Pages 1583-1594

  Lee, Hun J ^a   Thompson, James E ^a   Wang, Eunice S ^a   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

acute lymphoblastic leukemia; imatinib resistance; Philadelphia chromosome; tyrosine kinase inhibitors

Indexed keywords

ASPARAGINASE; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; CYTARABINE; DANUSERTIB; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FINGOLIMOD; IKAROS TRANSCRIPTION FACTOR; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; ORGANIC CATION TRANSPORTER 1; PREDNISONE; SORAFENIB; VINCRISTINE; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BCR ABL FUSION GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FUSION GENE; GENE MUTATION; GRAFT REJECTION; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA REMISSION; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM, RESIDUAL; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STEM CELL TRANSPLANTATION;

EID: 79953769788     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25690     Document Type: Review

References (101)

1. Pui CH, Evans WE., Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166-178. (Pubitemid 43076714)
2. Pulte D, Gondos A, Brenner H., Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009; 113: 1408-1411.
3. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
4. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109: 3189-3197. (Pubitemid 46572503)
5. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93: 3983-3993. (Pubitemid 29249848)
6. Wetzler M, Dodge RK, Mrozek K, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukemia Group B. Br J Haematol. 2004; 124: 275-288. (Pubitemid 38167977)
7. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A collaborative study of the Group Francais de Cytogenetique Hematologique. Blood. 1996; 87: 3135-3142.
8. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study. Blood. 1992; 80: 2983-2990. (Pubitemid 23004501)
9. Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992; 64: 97-100.
10. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM., Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994; 97: 60-65. (Pubitemid 24223635)
11. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G., Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol. 1997; 96: 601-610. (Pubitemid 27087248)
12. Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther. 1998; 40: 119-128. (Pubitemid 28280561)
13. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18: 547-561. (Pubitemid 30078536)
14. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002; 99: 1536-1543. (Pubitemid 34533023)
15. Forman SJ, O'Donnell MR, Nademanee AP, et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1987; 70: 587-588. (Pubitemid 17142952)
16. Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992; 79: 3067-3070.
17. Chao NJ, Blume KG, Forman SJ, Snyder DS., Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1995; 85: 3353-3354.
18. Snyder DS, Nademanee AP, O'Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia. 1999; 13: 2053-2058.
19. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009; 113: 4489-4496.
20. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaâresults of the prospective multicenter LALA-94 trial. Blood. 2002; 100: 2357-2366.
21. Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008; 112: 903-909.
22. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 1038-1042. (Pubitemid 32267973)
23. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 1965-1971. (Pubitemid 35001224)
24. Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005; 19: 1509-1516.
25. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006; 108: 1469-1477. (Pubitemid 44316110)
26. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006; 20: 1526-1532. (Pubitemid 44264094)
27. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007; 109: 3676-3678. (Pubitemid 46641715)
28. Hatta Y, Mizuta S, Ohtake S, et al. Promising outcome of imatinib-combined chemotherapy followed by allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 regimen [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 3090.
29. Tanguy-Schmidt A, de Labarthe A, Rousselot P, et al. Long-term results of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 3080.
30. Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol. 2010; 28: 15S.Abstract 6506.
31. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-2551. (Pubitemid 43882350)
32. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110: 2309-2315. (Pubitemid 47523149)
33. Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 2815.
34. Porkka K, Simonsson B, Dombret H, et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 2810.
35. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-2541. (Pubitemid 43882349)
36. Nowell PC, Hungerford D., A minute chromosome in human chronic granulocytic leukemia. Science. 1960; 132: 1497-1501.
37. Rowley JD., A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973; 243: 290-293.
38. Melo JV., The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996; 88: 2375-2384. (Pubitemid 26327486)
39. Russo C, Carroll A, Kohler S, et al. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1991; 77: 1050-1056.
40. Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991; 78: 2411-2418.
41. Melo JV, Gordon DE, Tuszynski A, Dhut S, Young BD, Goldman JM., Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. Blood. 1993; 81: 2488-2491. (Pubitemid 23147548)
42. Fielding AK, Richards SM, Lazarus HM, et al. Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 8.
43. Fielding AK, Goldstone AH., Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplant. 2008; 41: 447-453. (Pubitemid 351386709)
44. Esperou H, Boiron JM, Cayuela JM, et al. A potential graft-versus- leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant. 2003; 31: 909-918. (Pubitemid 36675748)
45. Yanada M, Naoe T, Iida H, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant. 2005; 36: 867-872. (Pubitemid 41655612)
46. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
47. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876-880. (Pubitemid 32743979)
48. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16: 2190-2196. (Pubitemid 35331833)
49. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002; 99: 3472-3475. (Pubitemid 34525335)
50. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002; 99: 1860-1862. (Pubitemid 34533064)
51. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008; 113: 985-994.
52. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007; 110: 727-734. (Pubitemid 47108165)
53. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ., Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002; 62: 7149-7153. (Pubitemid 36025227)
54. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003; 102: 276-283. (Pubitemid 36759665)
55. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005; 23: 4100-4109. (Pubitemid 46211315)
56. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004; 18: 401-408. (Pubitemid 38425851)
57. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96: 1070-1079. (Pubitemid 30616875)
58. Thomas J, Wang L, Clark RE, Pirmohamed M., Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004; 104: 3739-3745. (Pubitemid 39564452)
59. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007; 110: 4064-4072. (Pubitemid 350248463)
60. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000; 92: 1641-1650.
61. Kim CH, Broxmeyer HE., In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 1998; 91: 100-110. (Pubitemid 28018733)
62. Geay JF, Buet D, Zhang Y, et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res. 2005; 65: 2676-2683. (Pubitemid 40490067)
63. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J., Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res. 2006; 66: 5387-5393. (Pubitemid 43844965)
64. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008; 112: 3847-3855.
65. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004; 36: 453-461. (Pubitemid 38620028)
66. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S., Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A. 2006; 103: 16870-16875. (Pubitemid 44737345)
67. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 4500-4505. (Pubitemid 40740783)
68. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE., Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008; 112: 3348-3354.
69. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res. 2008; 14: 3881-3888.
70. Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007; 92: 401-404. (Pubitemid 350143551)
71. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7: 129-141. (Pubitemid 40248339)
72. Mahon F-X, Hayette S, Lagarde V, et al. Evidence that resistance to milotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008; 68: 9809-9816.
73. Cang S, Liu D., P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia [serial online]. J Hematol Oncol. 2008; 1: 15.
74. Thomas DA, Kantarjian HM, Cortes J, et al. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 2931.
75. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006; 24: 460-466. (Pubitemid 46630465)
76. Douer D, Watkins K, Mark L, Mohrbacher A, Yang AS, Avramis VI., Sustained and prolonged asparagine depletion by multiple doses of intravenous pegylated asparaginase in the treatment of adults with newly diagnosed acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 1928.
77. Rytting M, Earl M, Douer D, Muriera B, Advani A, Bleyer A., Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 1924.
78. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007; 109: 1408-1413. (Pubitemid 46239571)
79. Ravandi F, Thomas D, Kantarjian H, et al. Phase II study of combination of hyper-CVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 2921.
80. Rousselot P, Cayuela J-M, Recher C, et al. Dasatinib (Sprycel) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: results of the first 22 patients included in the EWALL-Ph-01 trial (on Behalf of the European Working Group on Adult ALL [EWALL]) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 2920.
81. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001; 97: 1999-2007. (Pubitemid 32239079)
82. Avramis IA, Laug WE, Sausville EA, Avramis VI., Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol. 2003; 52: 307-318. (Pubitemid 37352597)
83. Sleijfer S., With a little help from small friends: enhanced chemotherapeutic effects with imatinib. Eur J Cancer. 2006; 42: 808-810.
84. Thomas DA., Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program. 2007: 435-443.
85. Foa R, Vitale A, Guarini A, et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 305.
86. Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997; 89: 2602-2609. (Pubitemid 27143311)
87. Anderlini P, Sheth S, Hicks K, Ippoliti C, Giralt S, Champlin RE,. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation [letter]. Biol Blood Marrow Transplant. 2004; 10: 883-884. (Pubitemid 39625310)
88. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007; 109: 2791-2793. (Pubitemid 46482072)
89. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to post-transplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005; 106: 458-463. (Pubitemid 40981238)
90. Gambacorti-Passerini C, Cortes J, Kantarjian H, et al. Bosutinib (SKI-606) shows high tolerability and clinical activity in patients with Philadelphia chromosome positive leukemias [abstract]. Haematologica. 2008; 93 (suppl 1). Abstract 0403.
91. Pinilla-Ibarz J, Kantarjian HM, Cortes JE, et al. A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors [abstract]. J Clin Oncol. 2008; 26 (May 20 suppl). Abstract 7018.
92. Redaelli S, Piazza R, Rostagno R, et al. Determination of the activity profile of bosutinib, dasatinib and nilotinib against 18 imatinib resistant Bcr/Abl mutants [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 3220.
93. Jabbour E, Kantarjian HM, Jones D, Burton E, Cortes J., Clinical characteristics and outcome of patients (pts) with V299L BCR-ABL kinase domain (KD) mutation after therapy with tyrosine kinase inhibitors (TKIs) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 1105.
94. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005; 106: 3948-3954. (Pubitemid 41739036)
95. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117: 2408-2421. (Pubitemid 47494343)
96. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16: 401-412.
97. Van Etten RA, Chan WW, Zaleskas VM, et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 576.
98. Gontarewicz A, Brummendorf TH., Danusertib (formerly PHA-739358)âa novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res. 2010; 184: 199-214.
99. Rahmani M, Nguyen TK, Dent P, Grant S., The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007; 72: 788-795. (Pubitemid 47351213)
100. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O., Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009; 69: 3927-3936.
101. Goldstone AH, Prentice HG, Durrant IJ, et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for acute adult Philadelphia positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG 2993) [abstract]. Blood. 2001; 98. Abstract 856a.